Koichiro Tsugawa
Overview
Explore the profile of Koichiro Tsugawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamoto Y, Iwata H, Saji S, Takahashi M, Yoshinami T, Ueno T, et al.
J Clin Oncol
. 2025 Jan;
JCO2401673.
PMID: 39854662
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with...
2.
Shimo A, Tsugawa K, Sakamaki K, Kitajima M, Takishita M, Tazo M, et al.
Surg Case Rep
. 2024 Sep;
10(1):218.
PMID: 39292386
Background: Breast metastasis from small cell neuroendocrine carcinoma (SNEC) is very rare. In the present report, we describe a case of a female patient who was initially diagnosed with triple...
3.
Im S, Cortes J, Cescon D, Yusof M, Iwata H, Masuda N, et al.
NPJ Breast Cancer
. 2024 Sep;
10(1):79.
PMID: 39266535
In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among...
4.
Kawamoto H, Tsugawa K, Furuya Y, Sakamaki K, Kakimoto S, Kitajima M, et al.
Breast Cancer
. 2024 Apr;
31(4):695-704.
PMID: 38678120
Background: Ultrasound-guided percutaneous cryoablation (PCA) for early-stage breast cancer (ESBC) can be performed under local anesthesia in an outpatient clinic. This study continues a pilot stage to examine local control,...
5.
Hoshino A, Oana Y, Ohi Y, Maeda Y, Omori M, Takada Y, et al.
Acta Cytol
. 2024 Mar;
68(2):145-152.
PMID: 38555634
Introduction: Cancer genome analysis using next-generation sequencing requires adequate and high-quality DNA samples. Genomic analyses were conventionally performed using formalin-fixed paraffin-embedded sections rather than cytology samples such as cell block...
6.
Nakagawa S, Miyashita M, Maeda I, Goda A, Tada H, Amari M, et al.
Breast Cancer Res Treat
. 2024 Jan;
204(3):453-463.
PMID: 38180699
Background: Invasive lobular carcinoma (ILC) is distinct from invasive ductal carcinoma (IDC) in terms of their hormonal microenvironments that may require different therapeutic strategies. We previously reported that selective estrogen...
7.
Haraguchi T, Goto Y, Furuya Y, Nagai M, Kanemaki Y, Tsugawa K, et al.
Transl Cancer Res
. 2023 Jun;
12(5):1232-1240.
PMID: 37304551
Background: As of 2020, breast cancer is the most common type of cancer and the fifth most common cause of cancer-related deaths worldwide. The non-invasive prediction of axillary lymph node...
8.
Koizumi T, Sugishita Y, Suzuki-Takahashi Y, Nara K, Miyagawa T, Nakajima M, et al.
Cancer
. 2023 Apr;
129(16):2568-2580.
PMID: 37082910
Background: A couples' psycho-educational program called Oncofertility! Psycho-Education and Couple Enrichment (O!PEACE) therapy was created and its effect when provided before cancer treatment was examined. Methods: This multicenter randomized controlled...
9.
Haraguchi T, Kobayashi Y, Hirahara D, Kobayashi T, Takaya E, Nagai M, et al.
J Xray Sci Technol
. 2023 Apr;
31(3):627-640.
PMID: 37038802
Background: In breast cancer diagnosis and treatment, non-invasive prediction of axillary lymph node (ALN) metastasis can help avoid complications related to sentinel lymph node biopsy. Objective: This study aims to...
10.
Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, et al.
Cancer Med
. 2023 Mar;
12(9):10280-10293.
PMID: 36916728
Pembrolizumab plus chemotherapy improved progression-free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer with...